Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

Global Blood Therapeutics had developed Oxbryta that was used to treat haemolytic anaemia (excess breakdown of red blood cells) in patients aged 12 years and older who have sickle cell disease.

Oxbryta is manufactured as an oral therapy for patients with sickle cell disease. Hardiman began taking Oxbryta in 2020 under the belief that it would help manage his sickle cell disease.

Sickle cell disease summit hosted by HHS highlights advancements and challenges. Learn about the summit and the experiences ...

In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the ...

This electron microscope image provided by the National Institutes of Health in 2016 shows a blood cell altered by sickle cell disease, top. (National Center for Advancing Translational Sciences ...

The email explained that Pfizer, which manufactured and sold voxelotor under the brand name Oxbryta, voluntarily ... forward for people living with sickle cell disease, and to increase awareness ...